NEW YORK, May 22, 2018 /PRNewswire/ --
According to Grand View Research,Inc., the global stem cell market is projected to reach a value of USD 15.63 billion by 2025, while growing at a CAGR of 9.2%. The increasing number of research studies that aim at broadening the scope of stem cells associated
Recent results of an international trial of a stem cell transplant treatment shows that it could be a "game changer" for many patients with multiple sclerosis. According to Fortune, "Interim results from an international trial of a stem cell transplant treatment showed a much higher success rate than the control group, which received a drug treatment. MS is a disease that affects the brain, spinal cord, and immune system, leading to a number of disabilities. The stem cell treatment uses chemotherapy to wipe out a patient's immune system and then "re-boots" it using stem cells from the patient's blood and bone marrow that are unaffected by the disease."
International Stem Cell Corp. (OTCQB: ISCO) a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update announcing operating results for the three months ended March 31, 2018.
"This was a successful quarter for us both operationally and financially. We were able to decrease net loss by more than 70% compared to the prior year quarter, as well as successfully move forward with our research and development activities. As a result, we have significantly decreased our cash burn while moving forward with our clinical trial. These outcomes give us confidence in the Company's future," said Andrey Semechkin, PhD., CEO and Co-Chairman of ISCO.
Q1 2018 Financial Highlights
Recent Clinical Trial Highlights
About International Stem Cell Corporation - International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (http://www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (http://www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com."
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through optimized cell therapies that can treat cancer and immunological diseases by replacing patients' diseased cells. Recently, the company new scientific advisors in immuno-oncology and autoimmunity. The advisors hail from prestigious international institutions and collectively have both scientific and clinical expertise in cell therapies in these areas.
Omeros Corporation (NASDAQ: OMER) is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. On April 26, 2018, the company announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), specifically those patients who have persistent TMA despite modification of immunosuppressive therapy. This is the second breakthrough therapy drug designation for OMS721, which last year received the designation from FDA for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 is Omeros' lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. On March 28, 2018, the company announced that it has amended the protocol of its Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS). Per the protocol amendment, Canada-based ALS patients may now enroll in the ongoing Phase 3 NurOwn clinical trial. NurOwn utilizes a patient's own cells which have been engineered outside the body, to produce and secrete factors known to promote neuronal survival. NurOwn has the potential to be the first ALS treatment to improve patient functioning as a regenerative medicine.
Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Recently, Kite, a Gilead Company, announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000 square-foot site in Hoofddorp (SEGRO Park Amsterdam Airport) will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020. The facility will engineer and produce innovative cell therapies, including axicabtagene ciloleucel, a Chimeric Antigen Receptor T cell (CAR T) therapy that is currently under review by the European Medicines Agency and which is approved in the United Statesas Yescarta®. In addition to the Netherlands facility, Kite has recently purchased a new building in Santa Monica from Astellas Pharma Inc. that will be used for cell therapy research, development and the expansion of clinical manufacturing capabilities, and has leased a 26,000 square-foot facility in Gaithersburg, Maryland. The Maryland site will support the work of a new Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop adoptive cell therapies targeting patient-specific tumor neoantigens.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Media Contact: email@example.com +1-877-601-1879
Subscribe to our Free Newsletters!
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...
Bronchopulmonary dysplasia or chronic lung disease of infancy is seen in premature and low birth ...
Ear, nose and throat are important organs and disease in one area can affect the others. ENT ...View All